Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Clinical Practice Guideline for the Management of Luminal Crohn's Disease: The Toronto Consensus.

Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV Jr, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C, Bernstein CN.

Clin Gastroenterol Hepatol. 2019 Mar 7. pii: S1542-3565(19)30253-8. doi: 10.1016/j.cgh.2019.02.043. [Epub ahead of print]

PMID:
30853616
2.

Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus.

Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group.

Gastroenterology. 2015 May;148(5):1035-1058.e3. doi: 10.1053/j.gastro.2015.03.001. Epub 2015 Mar 4. Review.

PMID:
25747596
3.

Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus.

Steinhart AH, Panaccione R, Targownik L, Bressler B, Khanna R, Marshall JK, Afif W, Bernstein CN, Bitton A, Borgaonkar M, Chauhan U, Halloran B, Jones J, Kennedy E, Leontiadis GI, Loftus EV Jr, Meddings J, Moayyedi P, Murthy S, Plamondon S, Rosenfeld G, Schwartz D, Seow CH, Williams C.

Inflamm Bowel Dis. 2019 Jan 1;25(1):1-13. doi: 10.1093/ibd/izy247.

PMID:
30099529
4.

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.

Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C.

Health Technol Assess. 2011 Feb;15(6):1-244. doi: 10.3310/hta15060. Review.

5.

Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.

Boyapati RK, Torres J, Palmela C, Parker CE, Silverberg OM, Upadhyaya SD, Nguyen TM, Colombel JF.

Cochrane Database Syst Rev. 2018 May 12;5:CD012540. doi: 10.1002/14651858.CD012540.pub2. Review.

PMID:
29756637
6.

The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy.

Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, Leontiadis GI, Tse F, Mahadevan U, van der Woude CJ; IBD in Pregnancy Consensus Group; Canadian Association of Gastroenterology.

Gastroenterology. 2016 Mar;150(3):734-757.e1. doi: 10.1053/j.gastro.2015.12.003. Epub 2015 Dec 11. Review.

PMID:
26688268
7.

Methotrexate for induction of remission in refractory Crohn's disease.

McDonald JW, Wang Y, Tsoulis DJ, MacDonald JK, Feagan BG.

Cochrane Database Syst Rev. 2014 Aug 6;(8):CD003459. doi: 10.1002/14651858.CD003459.pub4. Review.

PMID:
25099640
8.

Methotrexate for induction of remission in refractory Crohn's disease.

McDonald JW, Tsoulis DJ, Macdonald JK, Feagan BG.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD003459. doi: 10.1002/14651858.CD003459.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;8:CD003459.

PMID:
23235598
9.

Aminosalicylates for induction of remission or response in Crohn's disease.

Lim WC, Wang Y, MacDonald JK, Hanauer S.

Cochrane Database Syst Rev. 2016 Jul 3;7:CD008870. doi: 10.1002/14651858.CD008870.pub2. Review.

PMID:
27372735
10.

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

Behm BW, Bickston SJ.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893. doi: 10.1002/14651858.CD006893. Review.

PMID:
18254120
11.

Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.

Chande N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK.

Cochrane Database Syst Rev. 2015 Oct 30;(10):CD000067. doi: 10.1002/14651858.CD000067.pub3. Review.

PMID:
26517527
12.

Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.

Sandborn WJ, Feagan BG, Lichtenstein GR.

Aliment Pharmacol Ther. 2007 Oct 1;26(7):987-1003. Review.

13.

Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease.

Singh S, Fumery M, Sandborn WJ, Murad MH.

Aliment Pharmacol Ther. 2018 Aug;48(4):394-409. doi: 10.1111/apt.14852. Epub 2018 Jun 19. Review.

PMID:
29920733
14.

Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis.

Lee MJ, Parker CE, Taylor SR, Guizzetti L, Feagan BG, Lobo AJ, Jairath V.

Clin Gastroenterol Hepatol. 2018 Dec;16(12):1879-1892. doi: 10.1016/j.cgh.2018.01.030. Epub 2018 Jan 31. Review.

PMID:
29374617
15.

Methotrexate for induction of remission in refractory Crohn's disease.

Alfadhli AA, McDonald JW, Feagan BG.

Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003459. Review. Update in: Cochrane Database Syst Rev. 2012;12:CD003459.

PMID:
15674908
16.

Methotrexate for induction of remission in refractory Crohn's disease.

Alfadhli AA, McDonald JW, Feagan BG.

Cochrane Database Syst Rev. 2003;(1):CD003459. Review. Update in: Cochrane Database Syst Rev. 2005;(1):CD003459.

PMID:
12535475
17.

Antibiotics for induction and maintenance of remission in Crohn's disease.

Townsend CM, Parker CE, MacDonald JK, Nguyen TM, Jairath V, Feagan BG, Khanna R.

Cochrane Database Syst Rev. 2019 Feb 7;2:CD012730. doi: 10.1002/14651858.CD012730.pub2. Review.

PMID:
30731030
18.

Corticosteroid-sparing treatments in patients with Crohn's disease.

Plevy SE.

Am J Gastroenterol. 2002 Jul;97(7):1607-17. Review.

PMID:
12135008
19.
20.

Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.

Khanna R, Preiss JC, MacDonald JK, Timmer A.

Cochrane Database Syst Rev. 2015 May 5;(5):CD007572. doi: 10.1002/14651858.CD007572.pub2. Review. Update in: Cochrane Database Syst Rev. 2016 Nov 25;11:CD007572.

PMID:
25942580

Supplemental Content

Support Center